Status:
COMPLETED
Efficacy, Tolerability, and Comfort of 0.3% Hypromellose Eyedrops in Patients Undergoing LASIK Surgery
Lead Sponsor:
Novartis Pharmaceuticals
Conditions:
Dry Eye
Eligibility:
All Genders
21-35 years
Phase:
PHASE4
Brief Summary
This study is designed to assess the tolerability and comfort of peri-operative 0.3% hypromellose eye drops in LASIK surgery patients and to assess whether pre-operative 0.3% hypromellose eye drops ad...
Eligibility Criteria
Inclusion
- Age 21 - 35
- Both sexes
- Seeking LASIK surgery at the Refractive Surgery Centre
- Meeting all established criteria for appropriateness for LASIK established by the treating center
Exclusion
- Any corneal pathology including scars, prior herpes keratitis, prior corneal transplant
- Any immuno-compromised state including cancer, HIV infection, Hepatitis B or C, or diabetes mellitus
- Requirement for any eye-drops for any reason (eg, dry eye or conjunctivitis) within 3 months from time of enrollment
- Anticipated refusal or inability to undergo planned post-operative visits or assessment
- Failure to meet all established criteria for appropriateness for LASIK
Key Trial Info
Start Date :
August 1 2009
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
January 1 2010
Estimated Enrollment :
170 Patients enrolled
Trial Details
Trial ID
NCT00909324
Start Date
August 1 2009
End Date
January 1 2010
Last Update
August 17 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Novartis Investigative Site
Delhi, India, 110088